Moreover, ongoing clinical trials explore the potential of EGFR-AS1 and its target EGFR gene, as well as MALAT1 and its target miR-124, as biomarkers and innovative therapeutic targets in oral cancer [111]. This evidence concerns the gene EGFR and lip and oral cavity carcinoma.